This correction is in line with the authors' observation that the rs6053666 rare allele C carriage is associated with decreased risk of breast cancer compared with the common GG genotype. As discussed in the article, the rs6053666 is predicted to participate in splicing regulation. No exonic splicing enhancer (ESE)-binding sites are predicted for the common allele T, whereas three ESE-binding sites are predicted for the rare allele C (FastSNP, F-SNP). In theory, defects in splicing might disturb proper translation of RNA for a normally functioning SRXN1 protein. As SRXN1 has antioxidative actions, reduced capacity to tolerate oxidative stress caused by radiation might explain the superior relapse-free survival of patients carrying the rs6053666 TT genotype compared with patients carrying the rare C allele.
It should also be corrected that in the multivariate analyses of breast cancer survival according to NRF2 and combined SRXN1 genotypes, the number of patients with rs2886162 GGþGA genotypes is 260 and 79 for the AA genotype, not 219 and 71, respectively (please see the corrected Supplementary Table S6 and Supplementary  Fig. S8 ). The authors regret these errors. 
